Dyne Therapeutics, Inc. 4

Douglas Kerr, CMO of Dyne Therapeutics, Inc., automatically sold 887 shares of common stock around $18.33 per share to cover tax withholdings from RSU vesting.

On June 16, 2026, Douglas Kerr, Chief Medical Officer of Dyne Therapeutics, Inc., effected an automatic sale of 887 shares of Dyne common stock at a weighted average price of approximately $18.33 per share, for proceeds of about $16,260, solely to cover tax withholding obligations arising from the vesting of previously granted restricted stock units under a pre-established Rule 10b5-1 compliant arrangement. Following this immaterial, non-discretionary sale, Kerr beneficially owned 169,155 shares of common stock, including 145,313 unvested RSUs, indicating that his overall equity exposure to the company remains substantial despite the routine tax-related transaction.

Filing Facts

CIK

1818794

Ticker

DYN

Form

4

Source Type

sec

Accession

0001814189-26-000002

Alert Tier

5